The explore was as soon as published as a preprint on researchsquare.com and has no longer yet been peek reviewed.
Key Takeaway
-
The response of IDH-wild kind recurrent glioblastoma to vascular endothelial growth mumble (VEGF) inhibitors can even be predicted by the pretreatment MRI disagreement enhancing pattern.
-
With predominantly disagreement enhancing lesions, bevacizumab prolongs development-free survival (PFS) in contrast with the alkalizing agent temozolomide.
-
With predominantly nonenhancing lesions, bevacizumab ends in shorter PFS in contrast with temozolomide.
Why This Matters
-
Bevacizumab is an increasing model of being historical for recurrent glioblastoma, nevertheless tumor responses fluctuate substantially between patients.
-
The disagreement enhancing pattern on well-liked pretreatment MRI is a legitimate and reproducible imaging biomarker to amass out patients for treatment with bevacizumab.
Look Create
-
Of the 65 patients with recurrent glioblastoma, 46 got bevacizumab and 19 got temozolomide as their secondary treatment.
-
Forty-5 patients had been labeled by two neuroradiologists as having disagreement enhancing lesion (CEL) dominant disease and 20 as having nonenhancing lesion (NEL) dominant disease.
-
Response to treatment was as soon as correlated to the disagreement enhancing pattern on pretreatment MRI.
Key Results
-
Bevacizumab was as soon as connected to longer PFS in the CEL dominant community (P = .031), and temozolomide was as soon as connected to longer PFS in the NEL dominant community (P = .022).
-
On univariate prognosis, bevacizumab was as soon as connected to longer PFS in the CEL community (hazard ratio [HR], 0.418; P = .038) nevertheless shorter PFS in the NEL dominant community (HR, 3.386; P = .031)
-
Quantitative prognosis printed cutoffs for the proportion of stable-enhancing tumor of 13.7% for the CEL community and 4.3% for the NEL community.
Obstacles
-
The explore was as soon as retrospective with dinky patient numbers.
-
Radiographic development was as soon as no longer confirmed by histology.
-
MRI did no longer incorporate developed tactics, such as perfusion-weighted imaging, to assess development and treatment response.
Disclosures
-
No funding source was as soon as reported, and the investigators did no longer instruct any financial conflicts.
Right here is a summary of a preprint study explore, “Difference Bettering Pattern on Pre-Therapy MRI predicts Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Comparability of Bevacizumab and Temozolomide Therapy.” The explore, which looked on researchsquare.com on January 10, has no longer been peek reviewed.
M. Alexander Otto is a health care provider assistant with a grasp’s level in medical science. He’s an award-winning medical journalist who labored for several predominant news shops sooner than joining Medscape and is an MIT Knight Science Journalism fellow. E-mail: aotto@mdedge.com.
For added news, educate Medscape on Facebook, Twitter, Instagram, and YouTube.
